Efforts toward oral bioavailability in factor VIIa inhibitors

Efforts toward developing orally bioavailable factor VIIa inhibitors starting from parenteral lead compound 1 are described. SAR resulted in compound 11 with improved physicochemical properties, leading to enhanced oral absorption in rat.